Comments on: Panchakarma for Autoimmune Conditions: Evidence Review and Clinical Considerations

By: Jessica Brown

Jessica Brown — Thu, 10 Sep 2026 02:41:05 +0000

for serious autoimmune conditions (lupus, multiple sclerosis, Crohn’s), delayung evidence-based immunotherapy in favor of Panchakarma could be genuinely harmful.

By: Mark Smith

Mark Smith — Fri, 28 Aug 2026 16:12:04 +0000

for autoimmune conditions on biologics (TNF inhibitors, IL-17 blockers), is Panchakarma contrsindicated or can it run parallel?

By: Tom Wilson

Tom Wilson — Mon, 17 Aug 2026 00:14:08 +0000

Overall, the evidence review presents a balanced view of what Panchakarma may offer as adjunctive therapy and what it cannot replace.

By: Emily Foster

Emily Foster — Thu, 13 Aug 2026 16:36:14 +0000

The precaution about monitoring thyroid function every four to six weeks during Panchakarma for Hashimoto’s patients seems practical.

By: Kevin Martin

Kevin Martin — Sun, 09 Aug 2026 19:23:44 +0000

I find the explanation of Ama and its resemblance to modern concepts of metabolic by products interesting.

By: Mark Bennett

Mark Bennett — Thu, 06 Aug 2026 17:38:21 +0000

The emphasis on coordinating care between Ayurvedic physicians and rheumatologists or endocrinologists is a necessary safety point.

By: Ashley Carter

Ashley Carter — Mon, 03 Aug 2026 00:00:54 +0000

It would be helpful to see longer term data on medication reduction after Panchakarma courses.

By: Tom Wilson

Tom Wilson — Thu, 30 Jul 2026 09:21:27 +0000

@Shruti timing Panchakarma relative to disease flares should it be done during remission only or can it be used to manage an active flare?

By: Susan Clark

Susan Clark — Thu, 30 Jul 2026 04:04:40 +0000

The article rightly notes that study quality varies and many trials have short follow up periods.

By: Anna Young

Anna Young — Tue, 28 Jul 2026 16:23:04 +0000

for autoimmune conditions on biologics (TNF inhibitors, IL-17 blpckers), is Panchakarma contraindicated or can it run parallel?